Seoul: SK Bioscience Co. on Wednesday reported a 2024 net loss of 50.1 billion won (US$34.7 million), turning from a profit of 22.3 billion won a year earlier. The company said in a regulatory filing that it continued to post an operating loss of 138.4 billion won for the year, compared with a loss of 12 billion won a year earlier. Revenue fell 27.6 percent to 267.5 billion won.

According to Yonhap News Agency, the significant downturn in SK Bioscience's financial performance highlights the challenges faced by the company over the past year. The transition from a profit to a substantial net loss signals potential issues in market conditions or operational difficulties that may have impacted the company's earnings.

The report from the Yonhap News Agency indicates that the drop in revenue was a major factor contributing to the overall financial decline. SK Bioscience's revenue for the year decreased by 27.6 percent, amounting to 267.5 billion won. This decline in revenue might reflect changes in demand for the company's products or increased competition in the industry.

The increase in operating losses is another critical aspect of SK Bioscience's financial report. The company reported an operating loss of 138.4 billion won, a significant rise from the previous year's operating loss of 12 billion won. This increase suggests that SK Bioscience may have faced higher operational costs or inefficiencies that impacted its profitability.

As SK Bioscience navigates these financial challenges, stakeholders and analysts will likely monitor the company's strategic responses to improve its fiscal health and return to profitability in future reports.